Spots Global Cancer Trial Database for cancer immunotherapy
Every month we try and update this database with for cancer immunotherapy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL) | NCT03946358 | Squamous Cell C... Anal Canal Canc... Cervical Cancer | Blood sample co... Tumor biopsies CT scan Atezolizumab UCPVax | 18 Years - 75 Years | Centre Hospitalier Universitaire de Besancon | |
| Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL) | NCT03946358 | Squamous Cell C... Anal Canal Canc... Cervical Cancer | Blood sample co... Tumor biopsies CT scan Atezolizumab UCPVax | 18 Years - 75 Years | Centre Hospitalier Universitaire de Besancon | |
| Universal Cancer Peptide-based Vaccination in Metastatic NSCLC | NCT02818426 | Metastatic Non-... | UCPVax | 18 Years - 89 Years | Centre Hospitalier Universitaire de Besancon | |
| Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL | NCT00274742 | Non-Hodgkin's L... | Blinatumomab (M... | 18 Years - | Amgen Research (Munich) GmbH | |
| Safety Study of Adoptive Transfer of Autologous IKDC-like Cells | NCT02661685 | Neoplasm Metast... | autologous IKDC... | 21 Years - 75 Years | National Defense Medical Center, Taiwan | |
| Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour | NCT04107142 | Colorectal Canc... Triple Negative... Sarcoma Nasopharyngeal ... Prostate Cancer Gastric Cancer | Adoptive Cell T... | 18 Years - | CytoMed Therapeutics Pte Ltd | |
| A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy | NCT02431572 | Intracranial Tu... Glioblastoma Melanoma | PBR PET Cancer Immunoth... Radiation and c... | 18 Years - | Massachusetts General Hospital | |
| A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1) | NCT05859217 | Lung Cancer NSCLC Stage IV Metastatic NSCL... Advanced NSCLC | Cabozantinib Atezolizumab | 18 Years - | University of Kansas Medical Center | |
| A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | NCT02521870 | Metastatic Mela... Head Neck Cance... | SD-101(1) Pembrolizumab SD-101(2) Pembrolizumab SD-101(3) Pembrolizumab | 18 Years - | Dynavax Technologies Corporation | |
| Study of Kinetics, Dosimetry & Safety of [18F]F-AraG, a Positron Emission Tomography Imaging Tracer in Healthy Humans | NCT02323893 | Cancer | [18F]F-AraG | 18 Years - | CellSight Technologies, Inc. | |
| A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | NCT02521870 | Metastatic Mela... Head Neck Cance... | SD-101(1) Pembrolizumab SD-101(2) Pembrolizumab SD-101(3) Pembrolizumab | 18 Years - | Dynavax Technologies Corporation | |
| Tracking Peripheral Blood Mononuclear Cells With Fluorine MRI | NCT02921373 | Adverse Reactio... | 19F Cell Sense-... MRI | 40 Years - 85 Years | Western University, Canada | |
| Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL | NCT00274742 | Non-Hodgkin's L... | Blinatumomab (M... | 18 Years - | Amgen Research (Munich) GmbH | |
| Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour | NCT04107142 | Colorectal Canc... Triple Negative... Sarcoma Nasopharyngeal ... Prostate Cancer Gastric Cancer | Adoptive Cell T... | 18 Years - | CytoMed Therapeutics Pte Ltd | |
| Study of Kinetics, Dosimetry & Safety of [18F]F-AraG, a Positron Emission Tomography Imaging Tracer in Healthy Humans | NCT02323893 | Cancer | [18F]F-AraG | 18 Years - | CellSight Technologies, Inc. | |
| Combination Therapy With GEN0101 and Pembrolizmub in Advanced Melanoma Patients PIb/PII | NCT03818893 | Advanced Melano... | Combination of ... | 20 Years - 85 Years | Osaka University | |
| A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant S. Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation | NCT00655161 | NSCLC | GI-4000 | 18 Years - | GlobeImmune | |
| GI Complications in Cancer Immunotherapy Patients | NCT02784366 | Malignant Melan... | 18 Years - | Massachusetts General Hospital | ||
| Prospective Cohort Study on the Clinical Trajectory of Resected Hepatocellular Carcinoma | NCT03267641 | Hepatocellular ... | 21 Years - 80 Years | National Cancer Centre, Singapore | ||
| Investigating the Biomarkers in Tumor and Peripheral Blood to Evaluate the Efficacy of Cancer Immunotherapy in Chest Cancer Patients | NCT05789498 | Lung Cancer Esophageal Canc... | In vitro stimul... | 18 Years - 80 Years | The First Affiliated Hospital of Soochow University | |
| Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint Inhibitors | NCT04169321 | Solid Tumor, Un... Lymphoma | Single Arm | 18 Years - | Cytosite Biopharma Inc. | |
| A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1) | NCT05859217 | Lung Cancer NSCLC Stage IV Metastatic NSCL... Advanced NSCLC | Cabozantinib Atezolizumab | 18 Years - | University of Kansas Medical Center | |
| A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy | NCT02431572 | Intracranial Tu... Glioblastoma Melanoma | PBR PET Cancer Immunoth... Radiation and c... | 18 Years - | Massachusetts General Hospital | |
| A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy | NCT02431572 | Intracranial Tu... Glioblastoma Melanoma | PBR PET Cancer Immunoth... Radiation and c... | 18 Years - | Massachusetts General Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
